Europe Lung Cancer Therapeutics Market – Industry Trends and Forecast to 2026

  • Healthcare IT
  • Published Report
  • Apr 2019
  • Europe
  • 350 Pages
  • No of Tables: 30
  • No of Figures: 252

Europe Lung Cancer Therapeutics Market By By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumors, Mediastinal Tumors, Mesothelioma, Chest Wall Tumors), Molecule Type (Small Molecules, Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors, Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Others), Therapy Type (Single Drug Therapy, Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online, Others), Country (U.K., Germany, Spain, France, Italy, Netherlands, Switzerland, Turkey, Belgium, Russia, Rest of Europe) – Industry Trends and Forecast to 2026

The lung cancer is type of cancer which decreases the efficiency of lungs to supply oxygen to the bloodstream. This is one of the most forms of cancers which accounts for the highest mortality rates. The lung cancer can be categorized as an uncontrolled growth of cell in the lungs. The main cause of lung cancers is pipes, cigarette smoking, cigar smoking, and asbestos exposure. Almost around 80.0% of the total lung cancers are non-small cell lung cancer. This kind of cancer is distinguished by their size as they are seen under the microscope. The most common symptoms of lung cancer are coughing, weight loss, chest pains, and shortness of breath. Lung cancers can be treated by various types of therapies like vaccines, radiation therapy, chemotherapy, and immunotherapies.

Europe lung cancer therapeutics market is expected to register a healthy CAGR in the forecast period of 2019 to 2026.

Segmentation: Europe Lung Cancer Therapeutics Market

Europe lung cancer therapeutics market is segmented into seven notable segments which are cancer type, molecule type, drug class, treatment type, therapy type, end user, distribution channel.

  • On the basis of cancer type, the market is segmented into non-small cell lung cancer, metastatic lung cancer, mesothelioma, chest wall tumors, pulmonary neuroendocrine tumors, mediastinal tumors.
  • On the basis of molecule type, the market is segmented into small molecules, biologics.
  • On the drug class, the market is segmented into alkylating agents, antimetabolites, mitotic inhibitors, multikinase inhibitors, EGFR inhibitors, others.
  • On the basis of treatment type, the market is segmented into radiation therapy, chemotherapy, targeted therapy, immunotherapy, and other drugs.
  • On the basis of therapy type, the market is segmented into single drug therapy, combination therapy.
  • On the basis of end user, the market is segmented into hospitals, specialty clinics, homecare, others.
  • On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online and others.

Competitive Analysis: Europe Lung Cancer Therapeutics Market

Some of the prominent players operating in this market are Takeda Pharmaceutical Company Limited, ONO PHARMACEUTICAL CO., LTD., F. Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly and Company., AstraZeneca, Boehringer Ingelheim International GmbH, Merck & Co., Inc., CELGENE CORPORATION, AMGEN INC., Sanofi, Johnson & Johnson Services, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., ALLERGAN, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., and many others.

Recent Development

  • In March 2019, the European Commission approved the Roche’s Tecentriq in combination with the Avastin and chemotherapy for initially treating the people with a certain form of metastatic lung cancer. This strategy would help the company in expanding their business in the European region.
  •  In December 2018, the European Commission approved Keytruda for treating the adjuvant of adults with the lymph node involvement and the stage III melanoma who have undergone the complete resection. This would help in expanding the company in European region.

Research Methodology: Europe Lung Cancer Therapeutics Market

Primary Respondents: Key Opinion Leaders (KOL’s): Manufacturer, Healthcare Professionals, Doctors, Nurses, Medical practitioners. Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and, National Sales Managers.


SKU-

LIST OF TABLES EUROPE LUNG CANCER THERAPEUTICS MARKET

TABLE 1 PREVALENCE OF SUBTYPES OF LUNG CARCINOMA IN SMOKERS AND NEVER-SMOKERS TABLE 2 COST OF TARGETED THERAPIES FOR THE TREATMENT OF NSCLC (2018) TABLE 3 COST OF IMMUNOTHERAPIES FOR THE TREATMENT OF NSCLC (2018) TABLE 4 SOME OF THE PIPELINE LUNG CANCER DRUGS ARE MENTIONED IN THE BELOW TABLE 5 AVERAGE COST OF LUNG CANCER TREATMENT (2018) TABLE 6 EUROPE LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 7 EUROPE NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 8 EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 9 EUROPE SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 10 EUROPE METASTATIC LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 11 EUROPE MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 12 EUROPE CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 13 EUROPE CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 14 EUROPE PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 15 EUROPE PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 16 EUROPE CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 17 EUROPE SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 18 EUROPE MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 19 EUROPE MESOTHELIOMA IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 20 EUROPE LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION) TABLE 21 EUROPE SMALL MOLECULE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 22 EUROPE BIOLOGICS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 23 EUROPE LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION) TABLE 24 EUROPE ALKYLATING AGENTS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 25 EUROPE ANTIMETABOLITES IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 26 EUROPE MITOTIC INHIBITORS PRODUCTS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 27 EUROPE MULTIKINASE INHIBITORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 28 EUROPE EGFR INHIBITORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 29 EUROPE OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 30 EUROPE LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 31 EUROPE RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 32 EUROPE RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 33 EUROPE CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 34 EUROPE CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 35 EUROPE TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 36 EUROPE TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 37 EUROPE IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 38 EUROPE IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 39 EUROPE OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 40 EUROPE LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION) TABLE 41 EUROPE SINGLE DRUG THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 42 EUROPE COMBINATION DRUG THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 43 EUROPE LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 44 EUROPE HOSPITALS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 45 EUROPE SPECIALTY CLINICS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 46 EUROPE HOMECARE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 47 EUROPE OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 48 EUROPE LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 49 EUROPE HOSPITAL PHARMACY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 50 EUROPE RETAIL PHARMACY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 51 EUROPE ONLINE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 52 EUROPE OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 53 EUROPE LUNG CANCER THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION) TABLE 54 EUROPE LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 55 EUROPE NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 56 EUROPE SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 57 EUROPE CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 58 EUROPE PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 59 EUROPE SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 60 EUROPE CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 61 EUROPE MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 62 EUROPE LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION) TABLE 63 EUROPE LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION) TABLE 64 EUROPE LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 65 EUROPE CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 66 EUROPE RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 67 EUROPE TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 68 EUROPE IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 69 EUROPE LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION) TABLE 70 EUROPE LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 71 EUROPE LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 72 GERMANY LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 73 GERMANY NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 74 GERMANY SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 75 GERMANY CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 76 GERMANY PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 77 GERMANY SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 78 GERMANY CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 79 GERMANY MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 80 GERMANY LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION) TABLE 81 GERMANY LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION) TABLE 82 GERMANY LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 83 GERMANY CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 84 GERMANY RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 85 GERMANY TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 86 GERMANY IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 87 GERMANY LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION) TABLE 88 GERMANY LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 89 GERMANY LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 90 FRANCE LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 91 FRANCE NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 92 FRANCE SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 93 FRANCE CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 94 FRANCE PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 95 FRANCE SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 96 FRANCE CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 97 FRANCE MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 98 FRANCE LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION) TABLE 99 FRANCE LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION) TABLE 100 FRANCE LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 101 FRANCE CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 102 FRANCE RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 103 FRANCE TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 104 FRANCE IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 105 FRANCE LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION) TABLE 106 FRANCE LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 107 FRANCE LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 108 U.K. LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 109 U.K. NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 110 U.K. SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 111 U.K. CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 112 U.K. PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 113 U.K. SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 114 U.K. CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 115 U.K. MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 116 U.K. LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION) TABLE 117 U.K. LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION) TABLE 118 U.K. LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 119 U.K. CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 120 U.K. RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 121 U.K. TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 122 U.K. IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 123 U.K. LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION) TABLE 124 U.K. LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 125 U.K. LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 126 ITALY LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 127 ITALY NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE , 2017-2026 (USD MILLION) TABLE 128 ITALY SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 129 ITALY CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 130 ITALY PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 131 ITALY SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 132 ITALY CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 133 ITALY MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 134 ITALY LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION) TABLE 135 ITALY LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION) TABLE 136 ITALY LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 137 ITALY CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 138 ITALY RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 139 ITALY TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 140 ITALY IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 141 ITALY LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION) TABLE 142 ITALY LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 143 ITALY LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 144 SPAIN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 145 SPAIN NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 146 SPAIN SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 147 SPAIN CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 148 SPAIN PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 149 SPAIN SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 150 SPAIN CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 151 SPAIN MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 152 SPAIN LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION) TABLE 153 SPAIN LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION) TABLE 154 SPAIN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 155 SPAIN CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 156 SPAIN RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 157 SPAIN TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 158 SPAIN IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 159 SPAIN LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION) TABLE 160 SPAIN LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 161 SPAIN LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 162 SWITZERLAND LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 163 SWITZERLAND NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE , 2017-2026 (USD MILLION) TABLE 164 SWITZERLAND SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 165 SWITZERLAND CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 166 SWITZERLAND PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 167 SWITZERLAND SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 168 SWITZERLAND CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 169 SWITZERLAND MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 170 SWITZERLAND LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION) TABLE 171 SWITZERLAND LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION) TABLE 172 SWITZERLAND LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 173 SWITZERLAND CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 174 SWITZERLAND RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 175 SWITZERLAND TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 176 SWITZERLAND IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 177 SWITZERLAND LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION) TABLE 178 SWITZERLAND LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 179 SWITZERLAND LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 180 NETHERLANDS LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 181 NETHERLANDS NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE , 2017-2026 (USD MILLION) TABLE 182 NETHERLANDS SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 183 NETHERLANDS CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 184 NETHERLANDS PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 185 NETHERLANDS SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 186 NETHERLANDS CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 187 NETHERLANDS MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 188 NETHERLANDS LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION) TABLE 189 NETHERLANDS LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION) TABLE 190 NETHERLANDS LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 191 NETHERLANDS CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 192 NETHERLANDS RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 193 NETHERLANDS TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 194 NETHERLANDS IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 195 NETHERLANDS LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION) TABLE 196 NETHERLANDS LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 197 NETHERLANDS LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 198 BELGIUM LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 199 BELGIUM NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE , 2017-2026 (USD MILLION) TABLE 200 BELGIUM SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 201 BELGIUM CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 202 BELGIUM PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 203 BELGIUM SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 204 BELGIUM CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 205 BELGIUM MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 206 BELGIUM LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION) TABLE 207 BELGIUM LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION) TABLE 208 BELGIUM LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 209 BELGIUM CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 210 BELGIUM RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 211 BELGIUM TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 212 BELGIUM IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 213 BELGIUM LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION) TABLE 214 BELGIUM LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 215 BELGIUM LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 216 RUSSIA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 217 RUSSIA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE , 2017-2026 (USD MILLION) TABLE 218 RUSSIA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 219 RUSSIA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 220 RUSSIA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 221 RUSSIA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 222 RUSSIA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 223 RUSSIA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 224 RUSSIA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION) TABLE 225 RUSSIA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION) TABLE 226 RUSSIA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 227 RUSSIA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 228 RUSSIA RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 229 RUSSIA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 230 RUSSIA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 231 RUSSIA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION) TABLE 232 RUSSIA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 233 RUSSIA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 234 TURKEY LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 235 TURKEY NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE , 2017-2026 (USD MILLION) TABLE 236 TURKEY SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 237 TURKEY CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 238 TURKEY PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 239 TURKEY SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 240 TURKEY CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 241 TURKEY MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 242 TURKEY LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION) TABLE 243 TURKEY LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION) TABLE 244 TURKEY LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 245 TURKEY CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 246 TURKEY RADIOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 247 TURKEY TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 248 TURKEY IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 249 TURKEY LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION) TABLE 250 TURKEY LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 251 TURKEY LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 252 REST OF EUROPE LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions